A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer

A One‑Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer Non–muscle invasive bladder cancer is a common, slow-progressing form of bladder cancer that makes up a majority of the roughly half a million new cases diagnosed each year. For decades, doctors have relied on a weakened bacterium called BCG, an intravesical immunotherapy, as a standard treatment for early-stage disease, but it fails in about 30 to 40 percent of patients. EnGene is taking a different approach with detalimogene, an experimental, non-viral gene therapy designed to trigger a powerful but localized immune response right where the cancer lives in the bladder. We spoke with Ron Cooper, CEO of EnGene, about this therapy for non–muscle invasive bladder cancer, how its dual payload is meant to activate both an innate and adaptive immune response in the bladder, and the company’s $130 million financing at the end of 2025.

You can listen to A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer online on Radio and Podcast. Open the player on this page to stream the available audio.

A One Two Gene Therapy Punch to Non-Muscle Invasive Bladder Cancer is an episode from The Bio Report by Levine Media Group.

This episode is 23:52 long.

This episode was published on Feb 11, 2026.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from The Bio Report when more episodes are available from the podcast feed.